Monoclonal antibody FC-5.01, Directed against CD63 antigen, is internalized into cytoplasmic vesicles in the IIB-BR-G human breast cancer cell line

Hybridoma

Volumn 17, Issue 6, 1998, Pages 517-525

  Barrio, María Marcela ^a   Portela, Paula ^a   Mordoh, José ^a  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE ORANGE; ANTIBODY CONJUGATE; CD63 ANTIGEN; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FC 5 01; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM VESICLE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INTERNALIZATION; LYMPHOCYTE; MONOCYTE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SCATCHARD PLOT;

EID: 0032411458     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1998.17.517     Document Type: Article

References (38)

1. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, and Old LJ: Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A Phase I trial in patients with malignant melanoma. PNAS 1985;82:1242-1246.
2. LoBuglio AF, Saleh MN, Lee J, Khazaeli MB, Carrano R, Holden H, and Wheeler RH: Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I-Clinical aspects. J Natl Cancer Inst 1988;80:932-936.
3. Menard S, Tagliabue E, Canevari S, Fossati G, and Colnaghi MI: Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res 1983;43:1295-1300.
4. Hellström I, Garrigues HJ, Garrigues U, Hellström KE: Highly tumor-reactive, internalizing mouse monoclonal antibodies to Leyrelated cell surface antigen. Cancer Res 1990;50:2186-2190.
5. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, and Hellström KE: Cure of xenografted human carcinomas by BR96-Doxorubucin immunoconjugates. Science 1993;261:212-215.
6. Shan D, Ledbetter JA, and Press OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91:1644-1652.
7. Baselga J, and Mendelsohn J: Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 1994;67:127-154.
8. Mordoh J, Leis S, Bravo AI, Podhajcer OL, Ballare C, Capurro M, Kairiyama C, and Bover L: Description of a new monoclonal antibody, FC-2.15, reactive with human breast cancer and other human neoplasias. Int J Biol Markers 1994;9:125-134.
9. Ballare C, Barrio M, Portela P, and Mordoh J: Functional properties of FC-2.15, a monoclonal antibody that mediates human complement cytotoxicity against breast cancer cells. Cancer Immunol Immunother 1995;41:15-22.
10. Bover L, Barrio M, Slavutsky I, Bravo AI, Quintans C, Bagnati A, Lema B, Schiaffi J, Yomha R, and Mordoh J: Description of a new human breast cancer cell line, HB-BR-G, established from a primary undifferentiated tumor. Breast Cancer Res Treat 1991;19:47-56.
11. Bover L, Barrio M, Bravo AI, Slavutsky I, Larripa Y, Bolondi A, Ayala M, and Mordoh J: The human breast cancer cell line IIB-BR-G has amplified c-myc and c-fos oncogenes in vitro and is spontaneously metastatic in vivo. Cell Mol Biol 1998;44:493-504.
12. Barrio M, Bravo AI, Portela P, Hersey P, and Mordoh J: A novel monoclonal antibody to human melanoma-associated antigen CD63/ME491 recognizes a new epitope both in primary and metastatic melanoma. Hybridoma 1998;17:355-364.
13. Capurro M, Bover L, Portela P, Livingston P, and Mordoh J: FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis(x) hapten. Cancer Immunol Immunother 1998;45:334-337.
14. Soule HD, Vazquez J, Long A, Albert S, and Breunan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973;51:1409-1416.
15. Kairiyama C, Slavutsky I, Morvillo V, Larripa I, Bover L, Podhajcer O, and Mordoh J: Biologic, immunocytochemical and cytogenetic characterization of two new human melanoma cell lines: IIB-MEL-LES and IIB-MEL-IAN. Pigment Cell Res 1995;8:121-137.
16. Guerra L, Mordoh J, Slavtusky I, Larripa I, and Medrano EE: Characterization of IIB-MEL-J: A new and highly heterogeneous human melanoma cell line. Pigment Cell Res 1989;2:504-509.
17. Jaffe EA, Nachman RL, Becker CG, and Minnick CR: Culture of human endothelial cells derived from umbilical veins. J Clin Invest 1973;52:2745-2756.
18. Fracker PJ, and Speck JC: Protein and cell membrane iodination with sparingly soluble chloramide 1,3,4,6-tetrachloro-3a,6a-diphenylglycouril. Biochem Biophys Res Commun 1978;80:849-857.
19. Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci 1949;51:660.
20. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, and Sondel PM: Augmentation of antibody dependent cell mediated cytotoxicity following in vitro therapy with recombinant interleukin 2. Cancer Res 1990;50:5234-5239.
21. Chang K, Pai L, Batra J, Pastan I, and Willingham M: Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 1992;52:181-186.
22. Shih LB, Xuan H, Aminipot R, Steihn R, and Goldemberg D: In vitro and in vivo reactivity of internalizing antibody RS7 with human breast cancer. Cancer Res 1995;55(Suppl.):5857s-5863s.
23. Miyake M, and Hakomori S: A specific cell surface glycoconjugate controlling cell motility: Evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochemistry 1991;30:3328-3334.
24. Breul SD, Bradley KH, Hance AJ, Schafer MP, Berg RA, Crystal RG, and Bradley K: Control of collagen production by human diploid lung fibroblasts. J Biol Chem 1980;255:5250-5260.
25. Hindenburg AA, Gervasoni JE Jr., Krishna S, Steward VJ, Rosado M, Lutzky J, Bhalla K, Baker MA, and Taub RN: Intracellular distribution and pharmacokinetics of Daunomycin in anthracycline-sensitive and resistant HL-60 cells. Cancer Res 1989;49:4607-4614.
26. Morgan A, Sullivan W, Graves S, and Woodhouse C: Murine monoclonal IgG3 to human colorectal tumor associated antigens: Enhancement of antibody-dependent cell mediated cytotoxicity by interleukin 2. Cancer Res 1989;49:2773-2776.
27. Munn D, and Cheung N: Interleukine-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against melanoma. Cancer Res 1987;47:6600-6605.
28. Berditchevsky F, Zutter MM, and Hemler E: Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins). Mol Biol Cell 1996;7:193-207.
29. Radford KJ, Thorne RF, and Hersey P: CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and β1 integrins in human melanoma. Biochem Biophys Res Commun 1996;222:13-28.
30. Hynes RO: Integrins: Versatility, modulation and signalling in cell adhesion. Cell 1992;69:11-25.
31. Juliano RL, and Haskill S: Signal transduction from the extracellular matrix. J Cell Biol 1993;120:577-585.
32. Melchiori A, Montarini R, Carlone S, Marchisio PC, Anichini A, Noonan DM, and Albini A: The α3β1 integrin is involved in melanoma cell migration and invasion. Exp Cell Res 1995;219:233-242.
33. Radford KJ, Thorne RF, and Hersey P: Regulation of tumor cell motility and migration by CD63 in human melanoma cell line. J Immunol 1997;158:3353-3358.
34. Atkinson B, Ernst CS, Christ BFD, Ross AH, Clark WH, Herlyn M, Herlyn D, Maul G, Steplewski Z, and Koprowsky H: Monoclonal antibody to a highly glycosilated protein that reacts in fixed tissue with melanoma and other tumors. Hybridoma 1985;4:243-255.
35. Azorsa DO, Hyman JA, and Hildreth JEK: CD63/Pt1gp40: A platelet activation antigen identical to the stage-specific, melanoma associated antigen ME491. Blood 1991;78:280-284.
36. Maecker HT, Todd SC, and Levy S: The Tetraspanin superfamily: Molecular facilitators. FASEB J 1997;11:428-442.
37. Wright MD, and Tomlinson MG: The ins and outs of the transmembrane 4 superfamily. Immunol Today 1994;15:588-594.
38. Christiaansen JE, Burnside SS, and Sears D: Apparent sensitivity of human K lymphocyts to the spatial orientation and organization of target cell-bound antibodies as measured by the efficiency of antibody-dependent cellular cytotoxicity (ADCC). J Immunol 1987;138:2236-2243.